Publications by authors named "Wan-Jen Hong"

Claim this Profile
P
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.
Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew Kuykendall, David Sallman, Wan-Jen Hong

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Marina Y Konopleva, Monique Dail, Naval G Daver, Jacqueline S Garcia, Brian A Jonas, Wan-Jen Hong

Clin Lymphoma Myeloma Leuk· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RWD-derived response in multiple myeloma.
Tao Xu, James Roose, Mellissa Williamson, Ahmed Sawas, Wan-Jen Hong

PLoS One· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Naval G Daver, Monique Dail, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Wan-Jen Hong

Blood· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.
Nathaniel J Myall, Samantha X Wang, Evan T Hall, Wesley H Witteles, Lawrence Leung, Wan-Jen Hong

Fed Pract· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
M Lia Palomba, Brian G Till, Steven I Park, Franck Morschhauser, Guillaume Cartron, Wan-Jen Hong

Clin Lymphoma Myeloma Leuk· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
Maria Lia Palomba, Guillaume Cartron, Leslie Popplewell, Vincent Ribrag, Jason Westin, Wan-Jen Hong

Clin Lymphoma Myeloma Leuk· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.
Shebli Atrash, Evelyn M Flahavan, Tao Xu, Esprit Ma, Sudeep Karve, Wan-Jen Hong

Blood Cancer J· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
Rebecca M Richards, Feifei Zhao, Katherine A Freitas, Kevin R Parker, Peng Xu, Wan-Jen Hong

Blood Cancer Discov· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Luciano J Costa, Faith E Davies, Gregory P Monohan, Tibor Kovacsovics, Nicholas Burwick, Wan-Jen Hong

Blood Adv· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019.
Shaji Kumar, Mellissa Williamson, Uzor Ogbu, Andy Surinach, Stella Arndorfer, Wan-Jen Hong

Cancer Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].
Jacqueline S Garcia, Ronan T Swords, Gail J Roboz, Meagan A Jacoby, Guillermo Garcia-Manero, Wan-Jen Hong

Leuk Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.
Jacqueline S Garcia, Ronan T Swords, Gail J Roboz, Meagan A Jacoby, Guillermo Garcia-Manero, Wan-Jen Hong

Leuk Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Shuichi Taniguchi, Takahiro Yamauchi, Ilseung Choi, Noriko Fukuhara, Jalaja Potluri, Wan-Jen Hong

Jpn J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Jonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, Philippe Moreau, Cyrille Touzeau, Wan-Jen Hong

Am J Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Daniel A Pollyea, Keith Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Wan-Jen Hong

Am J Hematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Wan-Jen Hong

Lancet Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Courtney D DiNardo, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Wan-Jen Hong

N Engl J Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L Lin, Wan-Jen Hong

J Clin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D DiNardo, Keith Pratz, Vinod Pullarkat, Brian A Jonas, Martha Arellano, Wan-Jen Hong

Blood· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells.
Andreas Reinisch, Daniel Thomas, M Ryan Corces, Xiaohua Zhang, Dita Gratzinger, Wan-Jen Hong

Nat Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.
Claire Mazumdar, Ying Shen, Seethu Xavy, Feifei Zhao, Andreas Reinisch, Wan-Jen Hong

Cell Stem Cell· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.
Ignacio Moraga, Gerlinde Wernig, Stephan Wilmes, Vitalina Gryshkova, Christian P Richter, Wan-Jen Hong

Cell· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Steven M Chan, Daniel Thomas, M Ryan Corces-Zimmerman, Seethu Xavy, Suchita Rastogi, Wan-Jen Hong

Nat Med· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary erythrocytosis, thrombocytosis and neutrophilia.
Wan-Jen Hong, Jason Gotlib

Best Pract Res Clin Haematol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis